Updated Results from the SPOTLIGHT and EV-302 Trials at ASCO With Ahsan Arozullah, MD, MPH

At this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, Oncology Data Advisor sat down for a conversation with Ahsan Arozullah, MD, MPH, Senior Vice President and Head of Oncology Development at Astellas. Dr. Arozullah provides insight into two of the Astellas’ trials being presented at the meeting, including:

• Final overall survival results of the phase 3 SPOTLIGHT study, investigating zolbetuximab plus mFOLFOX6 as first-line treatment for patients with CLDN18.2-positive, HER2-negative, locally advanced or unresectable/metastatic gastric or gastroesophageal junction adenocarcinoma (results presented by Dr. Kohei Shitara)
• Updated data from the phase 3 EV-302 trial of enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial carcinoma (results of cisplatin-eligible patients presented by Dr. Jens Bedke and results of cisplatin-ineligible patients presented by Dr. Michiel Simon Van Der Heijden)
• The significance of these results and how they speak to Astellas’ commitment to developing transformative therapies for people living with cancer

About Dr. Arozullah

Ahsan Arozullah, MD, MPH, is the Senior Vice President and Head of Oncology Development at Astellas. He leads development for the Oncology and Medical Specialties Therapeutic Areas teams, with an emphasis on pursuing innovative research across Astellas’ primary focus areas. Dr. Arozullah has more than 20 years of clinical research experience in pharmaceutical and academic settings. He collaborates with scientists, clinicians, and caretakers around the world to develop novel therapies that bring the highest value to patients.